These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 25851829)

  • 1. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
    Marti JL; Jain KS; Morris LG
    Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
    Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
    Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
    Corrêa NL; de Sá LV; de Mello RC
    Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
    Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
    Bhattacharyya N; Chien W
    Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
    Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
    Reiners C; Schneider R; Platonova T; Fridman M; Malzahn U; Mäder U; Vrachimis A; Bogdanova T; Krajewska J; Elisei R; Vaisman F; Mihailovic J; Costa G; Drozd V
    Front Endocrinol (Lausanne); 2020; 11():381. PubMed ID: 32754115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Italian cancer figures, report 2013: Multiple tumours.
    AIRTUM Working Group
    Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study.
    Wu W; Li S; Xu K; Meng Z
    Endokrynol Pol; 2023; 74(3):260-270. PubMed ID: 37335064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
    Pasqual E; Schonfeld S; Morton LM; Villoing D; Lee C; Berrington de Gonzalez A; Kitahara CM
    J Clin Oncol; 2022 May; 40(13):1439-1449. PubMed ID: 35044839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study.
    Piscopo L; Volpe F; Nappi C; Zampella E; Manganelli M; Matrisciano F; Totaro P; Pace L; Maurea S; Cuocolo A; Klain M
    Curr Oncol; 2022 Dec; 30(1):37-44. PubMed ID: 36661652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study.
    Spanogle JP; Clarke CA; Aroner S; Swetter SM
    J Am Acad Dermatol; 2010 May; 62(5):757-67. PubMed ID: 20223559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult.
    Zhao X; Chen M; Qi X; Zhu H; Yang G; Guo Y; Dong Q; Yang Q
    Front Endocrinol (Lausanne); 2021; 12():805194. PubMed ID: 35154006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer.
    Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG
    J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of second malignancies among survivors of pediatric thyroid cancer.
    Adly MH; Sobhy M; Rezk MA; Ishak M; Afifi MA; Shafie AE; Ali MA; Zekri W; Alfaar AS; Rashed WM
    Int J Clin Oncol; 2018 Aug; 23(4):625-633. PubMed ID: 29492793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
    Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
    Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in the risk and burden of second primary malignancy among survivors of smoking-related cancers in the United States.
    Adjei Boakye E; Buchanan P; Hinyard L; Osazuwa-Peters N; Simpson MC; Schootman M; Piccirillo JF
    Int J Cancer; 2019 Jul; 145(1):143-153. PubMed ID: 30613963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.
    Mei X; Yao X; Feng F; Cheng W; Wang H
    BMC Cancer; 2021 May; 21(1):543. PubMed ID: 33980182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?
    Souza MC; Momesso DP; Vaisman F; Vieira Neto L; Martins RA; Corbo R; Vaisman M
    Arch Endocrinol Metab; 2016 Feb; 60(1):9-15. PubMed ID: 26222230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.